openPR Logo
Press release

Developments in Gene Therapy for Ocular Diseases

08-25-2022 04:17 PM CET | Health & Medicine

Press release from: SAE Media Group

The Ophthalmic drugs industry continues to expand year on year, with an ageing population there is continual demand for advancements in ophthalmic treatments. This year's Ophthalmic Drugs Conference will have a key focus on gene therapy and artificial intelligence with developments on the latest drug pipelines and clinical trials.

The conference will convene on 21 - 22 November 2022 in London, UK, this year attendees will hear from industry giants about the developments being made in the ophthalmics and gene therapy field.

Interested parties can register at http://ophthlamicdrugs.com/PROR - register by 30 September to save £100.

The 5th annual conference will have a more in-depth discussion about the Developments in Gene Therapy for Ocular Diseases, with presentations and keynote speakers.

Use of Antisense Oligonucleotides for the Treatment of Inherited Retinal Diseases
•Antisense oligonucleotides have shown much promise in Ph1/2 Clinical Trials in LCA10 and Usher's Syndrome
•Lessons learned from Ph 2/3 trial with Sepofarsen for LCA10
•Latest trial data from Interim Analyses for Ultevursen for Usher's syndrome and non-syndromic Retinitis Pigmentosa
Led by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics

Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy
•LHON, a rare disease with high unmet medical need
•Development of Lumevoq Gene Therapy to treat ND4 LHON patients Developments in Gene Therapy for Ocular Diseases Drug Delivery Regulatory pathways
•Key learnings from recent data
Led by: Magali Taiel, Chief Medical Officer, Gensight Biologics

Ocular Inflammation associated with Gene and Cell Therapy
•Immune privilege and the eye
•Inflammation and gene therapy
•Inflammation and cell-based therapy
•What to look for….
Led by: Virginia Calder, Professor of Ocular
Immunology, University College London
Strengthening the Therapeutic Landscape for Inherited Retinal Diseases Using Genome Editing with AAV Vectors & CRISPR/Cas9 Technologies
•Expanding on the clinical development of novel gene therapies including SPVN06
•The benefits of designing gene therapies to act independently of the causative gene mutation
•An introduction to new clinical trials and future workings
Led by: Daniel Chung, Chief Medical Officer, Sparing Vision

To find out more about the line - up of the esteemed speakers for the conference and to download a complimentary brochure please visit http://ophthlamicdrugs.com/PROR

For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk

For media enquiries or a press pass contact Marketing, Simi Sapal on +44 (0) 20 7827 6162 or email ssapal@smi-online.co.uk

Ophthalmic Drugs
21-22 November 2022
London, UK
#OphthalmicDrugs
Sponsor: The Technology Partnership | Celanese
http://ophthlamicdrugs.com/PROR

India House, 45 Curlew Street

--- ENDS ---

About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Developments in Gene Therapy for Ocular Diseases here

News-ID: 2716040 • Views:

More Releases from SAE Media Group

Launch of the C-UAS Hub Report 2025: Countering the Threat: A Comprehensive Review of National C-UAS Programs
Launch of the C-UAS Hub Report 2025: Countering the Threat: A Comprehensive Revi …
SAE Media Group, renowned for its sell-out Counter UAS Conferences and owner of the C-UAS Hub, is excited to announce the release of its first-ever C-UAS Hub Report 2025, titled "Countering the Threat: A Comprehensive Review of National C-UAS Programs." As drones continue to play an increasingly prominent role in both military and civilian sectors, the demand for effective Counter UAS solutions is growing rapidly. NATO allies are making significant investments
How MilSatCom has transformed warfare and continues to shape the battlefield.
How MilSatCom has transformed warfare and continues to shape the battlefield.
The advancement of space-based communications technologies, including the ever-increasing presence of military satellites for electronic and signals intelligence purposes, has dramatically changed the way wars are fought down on Earth. From the launch of the first satellite communications network to the cutting-edge technology that is still in development, below we take a look at how far MilSatCom has come. A brief history of MilSatCom The first military communications satellites were launched by the
Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
SAE Media Group reports: Conference co-chairs invite delegates to join the anticipated 6th Annual 3D Cell Culture Conference SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. The 2023 Conference theme is on exploring the implementation of complex in-vitro models for drug development Visit the website at http://www.3d-cellculture.com/PR2 to find out
Exploring the Implementation of Complex In-vitro Models for Drug Development
Exploring the Implementation of Complex In-vitro Models for Drug Development
SAE Media Group reports: Agenda and speaker overview released for the 6th Annual 3D Cell Culture Conference, London, UK SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. 3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to

All 5 Releases


More Releases for Gene

DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034" The DNA and Gene Cloning Services Market Size is valued
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period? The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks. The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal